Pharma & Healthcare

Global Recombinant Protein Biopharmaceuticals Market Research Report 2025

The global market for Recombinant Protein Biopharmaceuticals was valued at US$ 177865 million in the year 2024 and is projected to reach a revised size of US$ 312704 million by 2031, growing at a CAGR of 8.5% during the forecast period.
Recombinant protein biopharmaceuticals are therapeutic proteins produced through recombinant DNA technology, in which genes encoding the desired protein are inserted into host cells (such as bacteria, yeast, or mammalian cells) for expression and large-scale production. These biologic drugs mimic or enhance natural proteins in the human body and are widely used in treating cancers, autoimmune diseases, metabolic disorders, and infectious diseases.
North American market for Recombinant Protein Biopharmaceuticals is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Recombinant Protein Biopharmaceuticals is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Recombinant Protein Biopharmaceuticals in Cancers is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Recombinant Protein Biopharmaceuticals include Novo Nordisk, Amgen, Eli Lilly, Sanofi, Bayer, Bristol-Myers Squibb, GlaxoSmithKline, AbbVie, Sandoz, Biogen, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Recombinant Protein Biopharmaceuticals, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Protein Biopharmaceuticals.
The Recombinant Protein Biopharmaceuticals market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Recombinant Protein Biopharmaceuticals market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Recombinant Protein Biopharmaceuticals companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novo Nordisk
Amgen
Eli Lilly
Sanofi
Bayer
Bristol-Myers Squibb
GlaxoSmithKline
AbbVie
Sandoz
Biogen
Pfizer
GenSci
3SBIO
Organon Pharma
Roche
Swedish Orphan Biovitrum
CSPC
Johnson & Johnson
Merck
Takeda
Segment by Type
Fusion Protein
Recombinant Growth Factor
Recombinant Hormone
Recombinant Interferon
Recombinant Interleukin
Recombinant Coagulation Factor
Other
Segment by Application
Cancers
Autoimmune Diseases
Metabolic Disorders
Infectious Diseases
By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Recombinant Protein Biopharmaceuticals company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Recombinant Protein Biopharmaceuticals Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Fusion Protein
1.2.3 Recombinant Growth Factor
1.2.4 Recombinant Hormone
1.2.5 Recombinant Interferon
1.2.6 Recombinant Interleukin
1.2.7 Recombinant Coagulation Factor
1.2.8 Other
1.3 Market by Application
1.3.1 Global Recombinant Protein Biopharmaceuticals Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Cancers
1.3.3 Autoimmune Diseases
1.3.4 Metabolic Disorders
1.3.5 Infectious Diseases
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Recombinant Protein Biopharmaceuticals Market Perspective (2020-2031)
2.2 Global Recombinant Protein Biopharmaceuticals Growth Trends by Region
2.2.1 Global Recombinant Protein Biopharmaceuticals Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Recombinant Protein Biopharmaceuticals Historic Market Size by Region (2020-2025)
2.2.3 Recombinant Protein Biopharmaceuticals Forecasted Market Size by Region (2026-2031)
2.3 Recombinant Protein Biopharmaceuticals Market Dynamics
2.3.1 Recombinant Protein Biopharmaceuticals Industry Trends
2.3.2 Recombinant Protein Biopharmaceuticals Market Drivers
2.3.3 Recombinant Protein Biopharmaceuticals Market Challenges
2.3.4 Recombinant Protein Biopharmaceuticals Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Recombinant Protein Biopharmaceuticals Players by Revenue
3.1.1 Global Top Recombinant Protein Biopharmaceuticals Players by Revenue (2020-2025)
3.1.2 Global Recombinant Protein Biopharmaceuticals Revenue Market Share by Players (2020-2025)
3.2 Global Top Recombinant Protein Biopharmaceuticals Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Recombinant Protein Biopharmaceuticals Revenue
3.4 Global Recombinant Protein Biopharmaceuticals Market Concentration Ratio
3.4.1 Global Recombinant Protein Biopharmaceuticals Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Recombinant Protein Biopharmaceuticals Revenue in 2024
3.5 Global Key Players of Recombinant Protein Biopharmaceuticals Head office and Area Served
3.6 Global Key Players of Recombinant Protein Biopharmaceuticals, Product and Application
3.7 Global Key Players of Recombinant Protein Biopharmaceuticals, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Recombinant Protein Biopharmaceuticals Breakdown Data by Type
4.1 Global Recombinant Protein Biopharmaceuticals Historic Market Size by Type (2020-2025)
4.2 Global Recombinant Protein Biopharmaceuticals Forecasted Market Size by Type (2026-2031)
5 Recombinant Protein Biopharmaceuticals Breakdown Data by Application
5.1 Global Recombinant Protein Biopharmaceuticals Historic Market Size by Application (2020-2025)
5.2 Global Recombinant Protein Biopharmaceuticals Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Recombinant Protein Biopharmaceuticals Market Size (2020-2031)
6.2 North America Recombinant Protein Biopharmaceuticals Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Recombinant Protein Biopharmaceuticals Market Size by Country (2020-2025)
6.4 North America Recombinant Protein Biopharmaceuticals Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Recombinant Protein Biopharmaceuticals Market Size (2020-2031)
7.2 Europe Recombinant Protein Biopharmaceuticals Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Recombinant Protein Biopharmaceuticals Market Size by Country (2020-2025)
7.4 Europe Recombinant Protein Biopharmaceuticals Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Recombinant Protein Biopharmaceuticals Market Size (2020-2031)
8.2 Asia-Pacific Recombinant Protein Biopharmaceuticals Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Recombinant Protein Biopharmaceuticals Market Size by Region (2020-2025)
8.4 Asia-Pacific Recombinant Protein Biopharmaceuticals Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Recombinant Protein Biopharmaceuticals Market Size (2020-2031)
9.2 Latin America Recombinant Protein Biopharmaceuticals Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Recombinant Protein Biopharmaceuticals Market Size by Country (2020-2025)
9.4 Latin America Recombinant Protein Biopharmaceuticals Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Recombinant Protein Biopharmaceuticals Market Size (2020-2031)
10.2 Middle East & Africa Recombinant Protein Biopharmaceuticals Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Recombinant Protein Biopharmaceuticals Market Size by Country (2020-2025)
10.4 Middle East & Africa Recombinant Protein Biopharmaceuticals Market Size by Country (2026-2031)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Novo Nordisk
11.1.1 Novo Nordisk Company Details
11.1.2 Novo Nordisk Business Overview
11.1.3 Novo Nordisk Recombinant Protein Biopharmaceuticals Introduction
11.1.4 Novo Nordisk Revenue in Recombinant Protein Biopharmaceuticals Business (2020-2025)
11.1.5 Novo Nordisk Recent Development
11.2 Amgen
11.2.1 Amgen Company Details
11.2.2 Amgen Business Overview
11.2.3 Amgen Recombinant Protein Biopharmaceuticals Introduction
11.2.4 Amgen Revenue in Recombinant Protein Biopharmaceuticals Business (2020-2025)
11.2.5 Amgen Recent Development
11.3 Eli Lilly
11.3.1 Eli Lilly Company Details
11.3.2 Eli Lilly Business Overview
11.3.3 Eli Lilly Recombinant Protein Biopharmaceuticals Introduction
11.3.4 Eli Lilly Revenue in Recombinant Protein Biopharmaceuticals Business (2020-2025)
11.3.5 Eli Lilly Recent Development
11.4 Sanofi
11.4.1 Sanofi Company Details
11.4.2 Sanofi Business Overview
11.4.3 Sanofi Recombinant Protein Biopharmaceuticals Introduction
11.4.4 Sanofi Revenue in Recombinant Protein Biopharmaceuticals Business (2020-2025)
11.4.5 Sanofi Recent Development
11.5 Bayer
11.5.1 Bayer Company Details
11.5.2 Bayer Business Overview
11.5.3 Bayer Recombinant Protein Biopharmaceuticals Introduction
11.5.4 Bayer Revenue in Recombinant Protein Biopharmaceuticals Business (2020-2025)
11.5.5 Bayer Recent Development
11.6 Bristol-Myers Squibb
11.6.1 Bristol-Myers Squibb Company Details
11.6.2 Bristol-Myers Squibb Business Overview
11.6.3 Bristol-Myers Squibb Recombinant Protein Biopharmaceuticals Introduction
11.6.4 Bristol-Myers Squibb Revenue in Recombinant Protein Biopharmaceuticals Business (2020-2025)
11.6.5 Bristol-Myers Squibb Recent Development
11.7 GlaxoSmithKline
11.7.1 GlaxoSmithKline Company Details
11.7.2 GlaxoSmithKline Business Overview
11.7.3 GlaxoSmithKline Recombinant Protein Biopharmaceuticals Introduction
11.7.4 GlaxoSmithKline Revenue in Recombinant Protein Biopharmaceuticals Business (2020-2025)
11.7.5 GlaxoSmithKline Recent Development
11.8 AbbVie
11.8.1 AbbVie Company Details
11.8.2 AbbVie Business Overview
11.8.3 AbbVie Recombinant Protein Biopharmaceuticals Introduction
11.8.4 AbbVie Revenue in Recombinant Protein Biopharmaceuticals Business (2020-2025)
11.8.5 AbbVie Recent Development
11.9 Sandoz
11.9.1 Sandoz Company Details
11.9.2 Sandoz Business Overview
11.9.3 Sandoz Recombinant Protein Biopharmaceuticals Introduction
11.9.4 Sandoz Revenue in Recombinant Protein Biopharmaceuticals Business (2020-2025)
11.9.5 Sandoz Recent Development
11.10 Biogen
11.10.1 Biogen Company Details
11.10.2 Biogen Business Overview
11.10.3 Biogen Recombinant Protein Biopharmaceuticals Introduction
11.10.4 Biogen Revenue in Recombinant Protein Biopharmaceuticals Business (2020-2025)
11.10.5 Biogen Recent Development
11.11 Pfizer
11.11.1 Pfizer Company Details
11.11.2 Pfizer Business Overview
11.11.3 Pfizer Recombinant Protein Biopharmaceuticals Introduction
11.11.4 Pfizer Revenue in Recombinant Protein Biopharmaceuticals Business (2020-2025)
11.11.5 Pfizer Recent Development
11.12 GenSci
11.12.1 GenSci Company Details
11.12.2 GenSci Business Overview
11.12.3 GenSci Recombinant Protein Biopharmaceuticals Introduction
11.12.4 GenSci Revenue in Recombinant Protein Biopharmaceuticals Business (2020-2025)
11.12.5 GenSci Recent Development
11.13 3SBIO
11.13.1 3SBIO Company Details
11.13.2 3SBIO Business Overview
11.13.3 3SBIO Recombinant Protein Biopharmaceuticals Introduction
11.13.4 3SBIO Revenue in Recombinant Protein Biopharmaceuticals Business (2020-2025)
11.13.5 3SBIO Recent Development
11.14 Organon Pharma
11.14.1 Organon Pharma Company Details
11.14.2 Organon Pharma Business Overview
11.14.3 Organon Pharma Recombinant Protein Biopharmaceuticals Introduction
11.14.4 Organon Pharma Revenue in Recombinant Protein Biopharmaceuticals Business (2020-2025)
11.14.5 Organon Pharma Recent Development
11.15 Roche
11.15.1 Roche Company Details
11.15.2 Roche Business Overview
11.15.3 Roche Recombinant Protein Biopharmaceuticals Introduction
11.15.4 Roche Revenue in Recombinant Protein Biopharmaceuticals Business (2020-2025)
11.15.5 Roche Recent Development
11.16 Swedish Orphan Biovitrum
11.16.1 Swedish Orphan Biovitrum Company Details
11.16.2 Swedish Orphan Biovitrum Business Overview
11.16.3 Swedish Orphan Biovitrum Recombinant Protein Biopharmaceuticals Introduction
11.16.4 Swedish Orphan Biovitrum Revenue in Recombinant Protein Biopharmaceuticals Business (2020-2025)
11.16.5 Swedish Orphan Biovitrum Recent Development
11.17 CSPC
11.17.1 CSPC Company Details
11.17.2 CSPC Business Overview
11.17.3 CSPC Recombinant Protein Biopharmaceuticals Introduction
11.17.4 CSPC Revenue in Recombinant Protein Biopharmaceuticals Business (2020-2025)
11.17.5 CSPC Recent Development
11.18 Johnson & Johnson
11.18.1 Johnson & Johnson Company Details
11.18.2 Johnson & Johnson Business Overview
11.18.3 Johnson & Johnson Recombinant Protein Biopharmaceuticals Introduction
11.18.4 Johnson & Johnson Revenue in Recombinant Protein Biopharmaceuticals Business (2020-2025)
11.18.5 Johnson & Johnson Recent Development
11.19 Merck
11.19.1 Merck Company Details
11.19.2 Merck Business Overview
11.19.3 Merck Recombinant Protein Biopharmaceuticals Introduction
11.19.4 Merck Revenue in Recombinant Protein Biopharmaceuticals Business (2020-2025)
11.19.5 Merck Recent Development
11.20 Takeda
11.20.1 Takeda Company Details
11.20.2 Takeda Business Overview
11.20.3 Takeda Recombinant Protein Biopharmaceuticals Introduction
11.20.4 Takeda Revenue in Recombinant Protein Biopharmaceuticals Business (2020-2025)
11.20.5 Takeda Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Recombinant Protein Biopharmaceuticals Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Fusion Protein
Table 3. Key Players of Recombinant Growth Factor
Table 4. Key Players of Recombinant Hormone
Table 5. Key Players of Recombinant Interferon
Table 6. Key Players of Recombinant Interleukin
Table 7. Key Players of Recombinant Coagulation Factor
Table 8. Key Players of Other
Table 9. Global Recombinant Protein Biopharmaceuticals Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 10. Global Recombinant Protein Biopharmaceuticals Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 11. Global Recombinant Protein Biopharmaceuticals Market Size by Region (2020-2025) & (US$ Million)
Table 12. Global Recombinant Protein Biopharmaceuticals Market Share by Region (2020-2025)
Table 13. Global Recombinant Protein Biopharmaceuticals Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 14. Global Recombinant Protein Biopharmaceuticals Market Share by Region (2026-2031)
Table 15. Recombinant Protein Biopharmaceuticals Market Trends
Table 16. Recombinant Protein Biopharmaceuticals Market Drivers
Table 17. Recombinant Protein Biopharmaceuticals Market Challenges
Table 18. Recombinant Protein Biopharmaceuticals Market Restraints
Table 19. Global Recombinant Protein Biopharmaceuticals Revenue by Players (2020-2025) & (US$ Million)
Table 20. Global Recombinant Protein Biopharmaceuticals Market Share by Players (2020-2025)
Table 21. Global Top Recombinant Protein Biopharmaceuticals Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant Protein Biopharmaceuticals as of 2024)
Table 22. Ranking of Global Top Recombinant Protein Biopharmaceuticals Companies by Revenue (US$ Million) in 2024
Table 23. Global 5 Largest Players Market Share by Recombinant Protein Biopharmaceuticals Revenue (CR5 and HHI) & (2020-2025)
Table 24. Global Key Players of Recombinant Protein Biopharmaceuticals, Headquarters and Area Served
Table 25. Global Key Players of Recombinant Protein Biopharmaceuticals, Product and Application
Table 26. Global Key Players of Recombinant Protein Biopharmaceuticals, Date of Enter into This Industry
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Recombinant Protein Biopharmaceuticals Market Size by Type (2020-2025) & (US$ Million)
Table 29. Global Recombinant Protein Biopharmaceuticals Revenue Market Share by Type (2020-2025)
Table 30. Global Recombinant Protein Biopharmaceuticals Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 31. Global Recombinant Protein Biopharmaceuticals Revenue Market Share by Type (2026-2031)
Table 32. Global Recombinant Protein Biopharmaceuticals Market Size by Application (2020-2025) & (US$ Million)
Table 33. Global Recombinant Protein Biopharmaceuticals Revenue Market Share by Application (2020-2025)
Table 34. Global Recombinant Protein Biopharmaceuticals Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 35. Global Recombinant Protein Biopharmaceuticals Revenue Market Share by Application (2026-2031)
Table 36. North America Recombinant Protein Biopharmaceuticals Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 37. North America Recombinant Protein Biopharmaceuticals Market Size by Country (2020-2025) & (US$ Million)
Table 38. North America Recombinant Protein Biopharmaceuticals Market Size by Country (2026-2031) & (US$ Million)
Table 39. Europe Recombinant Protein Biopharmaceuticals Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 40. Europe Recombinant Protein Biopharmaceuticals Market Size by Country (2020-2025) & (US$ Million)
Table 41. Europe Recombinant Protein Biopharmaceuticals Market Size by Country (2026-2031) & (US$ Million)
Table 42. Asia-Pacific Recombinant Protein Biopharmaceuticals Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 43. Asia-Pacific Recombinant Protein Biopharmaceuticals Market Size by Region (2020-2025) & (US$ Million)
Table 44. Asia-Pacific Recombinant Protein Biopharmaceuticals Market Size by Region (2026-2031) & (US$ Million)
Table 45. Latin America Recombinant Protein Biopharmaceuticals Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 46. Latin America Recombinant Protein Biopharmaceuticals Market Size by Country (2020-2025) & (US$ Million)
Table 47. Latin America Recombinant Protein Biopharmaceuticals Market Size by Country (2026-2031) & (US$ Million)
Table 48. Middle East & Africa Recombinant Protein Biopharmaceuticals Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 49. Middle East & Africa Recombinant Protein Biopharmaceuticals Market Size by Country (2020-2025) & (US$ Million)
Table 50. Middle East & Africa Recombinant Protein Biopharmaceuticals Market Size by Country (2026-2031) & (US$ Million)
Table 51. Novo Nordisk Company Details
Table 52. Novo Nordisk Business Overview
Table 53. Novo Nordisk Recombinant Protein Biopharmaceuticals Product
Table 54. Novo Nordisk Revenue in Recombinant Protein Biopharmaceuticals Business (2020-2025) & (US$ Million)
Table 55. Novo Nordisk Recent Development
Table 56. Amgen Company Details
Table 57. Amgen Business Overview
Table 58. Amgen Recombinant Protein Biopharmaceuticals Product
Table 59. Amgen Revenue in Recombinant Protein Biopharmaceuticals Business (2020-2025) & (US$ Million)
Table 60. Amgen Recent Development
Table 61. Eli Lilly Company Details
Table 62. Eli Lilly Business Overview
Table 63. Eli Lilly Recombinant Protein Biopharmaceuticals Product
Table 64. Eli Lilly Revenue in Recombinant Protein Biopharmaceuticals Business (2020-2025) & (US$ Million)
Table 65. Eli Lilly Recent Development
Table 66. Sanofi Company Details
Table 67. Sanofi Business Overview
Table 68. Sanofi Recombinant Protein Biopharmaceuticals Product
Table 69. Sanofi Revenue in Recombinant Protein Biopharmaceuticals Business (2020-2025) & (US$ Million)
Table 70. Sanofi Recent Development
Table 71. Bayer Company Details
Table 72. Bayer Business Overview
Table 73. Bayer Recombinant Protein Biopharmaceuticals Product
Table 74. Bayer Revenue in Recombinant Protein Biopharmaceuticals Business (2020-2025) & (US$ Million)
Table 75. Bayer Recent Development
Table 76. Bristol-Myers Squibb Company Details
Table 77. Bristol-Myers Squibb Business Overview
Table 78. Bristol-Myers Squibb Recombinant Protein Biopharmaceuticals Product
Table 79. Bristol-Myers Squibb Revenue in Recombinant Protein Biopharmaceuticals Business (2020-2025) & (US$ Million)
Table 80. Bristol-Myers Squibb Recent Development
Table 81. GlaxoSmithKline Company Details
Table 82. GlaxoSmithKline Business Overview
Table 83. GlaxoSmithKline Recombinant Protein Biopharmaceuticals Product
Table 84. GlaxoSmithKline Revenue in Recombinant Protein Biopharmaceuticals Business (2020-2025) & (US$ Million)
Table 85. GlaxoSmithKline Recent Development
Table 86. AbbVie Company Details
Table 87. AbbVie Business Overview
Table 88. AbbVie Recombinant Protein Biopharmaceuticals Product
Table 89. AbbVie Revenue in Recombinant Protein Biopharmaceuticals Business (2020-2025) & (US$ Million)
Table 90. AbbVie Recent Development
Table 91. Sandoz Company Details
Table 92. Sandoz Business Overview
Table 93. Sandoz Recombinant Protein Biopharmaceuticals Product
Table 94. Sandoz Revenue in Recombinant Protein Biopharmaceuticals Business (2020-2025) & (US$ Million)
Table 95. Sandoz Recent Development
Table 96. Biogen Company Details
Table 97. Biogen Business Overview
Table 98. Biogen Recombinant Protein Biopharmaceuticals Product
Table 99. Biogen Revenue in Recombinant Protein Biopharmaceuticals Business (2020-2025) & (US$ Million)
Table 100. Biogen Recent Development
Table 101. Pfizer Company Details
Table 102. Pfizer Business Overview
Table 103. Pfizer Recombinant Protein Biopharmaceuticals Product
Table 104. Pfizer Revenue in Recombinant Protein Biopharmaceuticals Business (2020-2025) & (US$ Million)
Table 105. Pfizer Recent Development
Table 106. GenSci Company Details
Table 107. GenSci Business Overview
Table 108. GenSci Recombinant Protein Biopharmaceuticals Product
Table 109. GenSci Revenue in Recombinant Protein Biopharmaceuticals Business (2020-2025) & (US$ Million)
Table 110. GenSci Recent Development
Table 111. 3SBIO Company Details
Table 112. 3SBIO Business Overview
Table 113. 3SBIO Recombinant Protein Biopharmaceuticals Product
Table 114. 3SBIO Revenue in Recombinant Protein Biopharmaceuticals Business (2020-2025) & (US$ Million)
Table 115. 3SBIO Recent Development
Table 116. Organon Pharma Company Details
Table 117. Organon Pharma Business Overview
Table 118. Organon Pharma Recombinant Protein Biopharmaceuticals Product
Table 119. Organon Pharma Revenue in Recombinant Protein Biopharmaceuticals Business (2020-2025) & (US$ Million)
Table 120. Organon Pharma Recent Development
Table 121. Roche Company Details
Table 122. Roche Business Overview
Table 123. Roche Recombinant Protein Biopharmaceuticals Product
Table 124. Roche Revenue in Recombinant Protein Biopharmaceuticals Business (2020-2025) & (US$ Million)
Table 125. Roche Recent Development
Table 126. Swedish Orphan Biovitrum Company Details
Table 127. Swedish Orphan Biovitrum Business Overview
Table 128. Swedish Orphan Biovitrum Recombinant Protein Biopharmaceuticals Product
Table 129. Swedish Orphan Biovitrum Revenue in Recombinant Protein Biopharmaceuticals Business (2020-2025) & (US$ Million)
Table 130. Swedish Orphan Biovitrum Recent Development
Table 131. CSPC Company Details
Table 132. CSPC Business Overview
Table 133. CSPC Recombinant Protein Biopharmaceuticals Product
Table 134. CSPC Revenue in Recombinant Protein Biopharmaceuticals Business (2020-2025) & (US$ Million)
Table 135. CSPC Recent Development
Table 136. Johnson & Johnson Company Details
Table 137. Johnson & Johnson Business Overview
Table 138. Johnson & Johnson Recombinant Protein Biopharmaceuticals Product
Table 139. Johnson & Johnson Revenue in Recombinant Protein Biopharmaceuticals Business (2020-2025) & (US$ Million)
Table 140. Johnson & Johnson Recent Development
Table 141. Merck Company Details
Table 142. Merck Business Overview
Table 143. Merck Recombinant Protein Biopharmaceuticals Product
Table 144. Merck Revenue in Recombinant Protein Biopharmaceuticals Business (2020-2025) & (US$ Million)
Table 145. Merck Recent Development
Table 146. Takeda Company Details
Table 147. Takeda Business Overview
Table 148. Takeda Recombinant Protein Biopharmaceuticals Product
Table 149. Takeda Revenue in Recombinant Protein Biopharmaceuticals Business (2020-2025) & (US$ Million)
Table 150. Takeda Recent Development
Table 151. Research Programs/Design for This Report
Table 152. Key Data Information from Secondary Sources
Table 153. Key Data Information from Primary Sources
Table 154. Authors List of This Report


List of Figures
Figure 1. Recombinant Protein Biopharmaceuticals Picture
Figure 2. Global Recombinant Protein Biopharmaceuticals Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Recombinant Protein Biopharmaceuticals Market Share by Type: 2024 VS 2031
Figure 4. Fusion Protein Features
Figure 5. Recombinant Growth Factor Features
Figure 6. Recombinant Hormone Features
Figure 7. Recombinant Interferon Features
Figure 8. Recombinant Interleukin Features
Figure 9. Recombinant Coagulation Factor Features
Figure 10. Other Features
Figure 11. Global Recombinant Protein Biopharmaceuticals Market Size by Application (2020-2031) & (US$ Million)
Figure 12. Global Recombinant Protein Biopharmaceuticals Market Share by Application: 2024 VS 2031
Figure 13. Cancers Case Studies
Figure 14. Autoimmune Diseases Case Studies
Figure 15. Metabolic Disorders Case Studies
Figure 16. Infectious Diseases Case Studies
Figure 17. Recombinant Protein Biopharmaceuticals Report Years Considered
Figure 18. Global Recombinant Protein Biopharmaceuticals Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 19. Global Recombinant Protein Biopharmaceuticals Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 20. Global Recombinant Protein Biopharmaceuticals Market Share by Region: 2024 VS 2031
Figure 21. Global Recombinant Protein Biopharmaceuticals Market Share by Players in 2024
Figure 22. Global Recombinant Protein Biopharmaceuticals Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 23. The Top 10 and 5 Players Market Share by Recombinant Protein Biopharmaceuticals Revenue in 2024
Figure 24. North America Recombinant Protein Biopharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. North America Recombinant Protein Biopharmaceuticals Market Share by Country (2020-2031)
Figure 26. United States Recombinant Protein Biopharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Canada Recombinant Protein Biopharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Europe Recombinant Protein Biopharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Europe Recombinant Protein Biopharmaceuticals Market Share by Country (2020-2031)
Figure 30. Germany Recombinant Protein Biopharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. France Recombinant Protein Biopharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. U.K. Recombinant Protein Biopharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Italy Recombinant Protein Biopharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Russia Recombinant Protein Biopharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Ireland Recombinant Protein Biopharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Asia-Pacific Recombinant Protein Biopharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Asia-Pacific Recombinant Protein Biopharmaceuticals Market Share by Region (2020-2031)
Figure 38. China Recombinant Protein Biopharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Japan Recombinant Protein Biopharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. South Korea Recombinant Protein Biopharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Southeast Asia Recombinant Protein Biopharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. India Recombinant Protein Biopharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Australia & New Zealand Recombinant Protein Biopharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Latin America Recombinant Protein Biopharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Latin America Recombinant Protein Biopharmaceuticals Market Share by Country (2020-2031)
Figure 46. Mexico Recombinant Protein Biopharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Brazil Recombinant Protein Biopharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Middle East & Africa Recombinant Protein Biopharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Middle East & Africa Recombinant Protein Biopharmaceuticals Market Share by Country (2020-2031)
Figure 50. Israel Recombinant Protein Biopharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 51. Saudi Arabia Recombinant Protein Biopharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 52. UAE Recombinant Protein Biopharmaceuticals Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 53. Novo Nordisk Revenue Growth Rate in Recombinant Protein Biopharmaceuticals Business (2020-2025)
Figure 54. Amgen Revenue Growth Rate in Recombinant Protein Biopharmaceuticals Business (2020-2025)
Figure 55. Eli Lilly Revenue Growth Rate in Recombinant Protein Biopharmaceuticals Business (2020-2025)
Figure 56. Sanofi Revenue Growth Rate in Recombinant Protein Biopharmaceuticals Business (2020-2025)
Figure 57. Bayer Revenue Growth Rate in Recombinant Protein Biopharmaceuticals Business (2020-2025)
Figure 58. Bristol-Myers Squibb Revenue Growth Rate in Recombinant Protein Biopharmaceuticals Business (2020-2025)
Figure 59. GlaxoSmithKline Revenue Growth Rate in Recombinant Protein Biopharmaceuticals Business (2020-2025)
Figure 60. AbbVie Revenue Growth Rate in Recombinant Protein Biopharmaceuticals Business (2020-2025)
Figure 61. Sandoz Revenue Growth Rate in Recombinant Protein Biopharmaceuticals Business (2020-2025)
Figure 62. Biogen Revenue Growth Rate in Recombinant Protein Biopharmaceuticals Business (2020-2025)
Figure 63. Pfizer Revenue Growth Rate in Recombinant Protein Biopharmaceuticals Business (2020-2025)
Figure 64. GenSci Revenue Growth Rate in Recombinant Protein Biopharmaceuticals Business (2020-2025)
Figure 65. 3SBIO Revenue Growth Rate in Recombinant Protein Biopharmaceuticals Business (2020-2025)
Figure 66. Organon Pharma Revenue Growth Rate in Recombinant Protein Biopharmaceuticals Business (2020-2025)
Figure 67. Roche Revenue Growth Rate in Recombinant Protein Biopharmaceuticals Business (2020-2025)
Figure 68. Swedish Orphan Biovitrum Revenue Growth Rate in Recombinant Protein Biopharmaceuticals Business (2020-2025)
Figure 69. CSPC Revenue Growth Rate in Recombinant Protein Biopharmaceuticals Business (2020-2025)
Figure 70. Johnson & Johnson Revenue Growth Rate in Recombinant Protein Biopharmaceuticals Business (2020-2025)
Figure 71. Merck Revenue Growth Rate in Recombinant Protein Biopharmaceuticals Business (2020-2025)
Figure 72. Takeda Revenue Growth Rate in Recombinant Protein Biopharmaceuticals Business (2020-2025)
Figure 73. Bottom-up and Top-down Approaches for This Report
Figure 74. Data Triangulation
Figure 75. Key Executives Interviewed
Choose Your Edition
Add to cart

Our team would be happy to assist you with your queries.

Contact us

About us

Accurate data, The latest market trends, And deeper research directions.

Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals

Latest reports

Useful links

Our Contacts

Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China

(+86) 159 1069 5232

sales@hengceresearch.com
hengceresearch.com

Allow cookies